Tamas Mir Named Senior Vice President, Finance; CFO Andrew D. C. LaFrence Resigns to Pursue New Opportunity
EAGAN, MN — August 6, 2019 — Biothera Pharmaceuticals, Inc. today announced the appointment of Tamas Mir as Senior Vice President, Finance with responsibility for all finance functions, Human Resources and Information Technology. Mr. Mir joined Biothera in 2012 as Corporate Controller and was promoted the following year to Vice President, Finance. Mr. Mir replaces Andrew D. C. LaFrence, who has left Biothera for a CFO position at another company.
“Tamas has played a leadership role at Biothera the past seven years. His in-depth knowledge of the Company and broad experience in all aspects of finance and accounting, including company sales and divestitures, are an excellent fit for Biothera’s business strategy,” said Richard G. Mueller, Biothera Pharmaceuticals Chief Executive Officer.
“We thank Andy for his many contributions to Biothera. When he joined the company, our expectations for an initial public offering were consistent with his career objectives and experience,” said Mueller. “Now that Biothera is on a different strategic path, we understand his decision to seek a CFO position at another company. We wish Andy well in his next endeavor.”
Mr. Mir has more than 30 years of accounting and finance experience, including senior management positions at public and private companies. As Biothera’s Vice President, Finance, he had an integral role in the financial aspects of the Company’s 2015 sale of Biothera Health Inc., a global and branded functional food, beverage and supplement ingredient business, to Kerry Group plc. Before joining Biothera, Mr. Mir was Vice President, Finance and Corporate Controller for UnitedHealth Group’s OptumInsight business, which provides information and technology enabled health services. He also held senior accounting and finance positions at Ally Financial, TCF Financial Corp., Carlson Wagonlit Travel and KPMG. Mr. Mir is a certified public accountant (inactive), chartered accountant Australia and New Zealand, and chartered global management accountant. He has a bachelor’s degree in business majoring in accounting from Deakin University in Melbourne, Australia.
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a novel dectin receptor agonist that reverses tumor-mediated immunosuppression while promoting antigen presentation to drive T cell activation and infiltration into tumors, and to enhance clinical benefit from immune checkpoint inhibitors. Biothera Pharmaceuticals is currently developing this platform drug through clinical research collaborations with Merck, Genentech, the Dana Farber Cancer Institute and the Big Ten Cancer Research Consortium in cancers that include triple negative breast cancer, advanced melanoma, colorectal cancer and non-small lung cell cancer.
Richard G. Mueller
Chief Executive Officer (Acting)
Biothera Pharmaceuticals, Inc.